Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? - Reply

被引：1
|
作者：
Moore, Malcolm J. [1 ]
Au, Heather Jane
Parulekar, Wendy
机构：
[1] Univ Toronto, Princess Margaret Hosp, NCI,Div Med Oncol & Hematol, Canada Clin Trials Grp Gastrointestinal Dis Commi, Toronto, ON, Canada
[2] Queens Univ, NCI, Canada Clin Trials Grp, Kingston, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 28期
关键词：
D O I：
10.1200/JCO.2007.13.1862
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4508 / 4508
页数：1
相关论文
共 50 条
  • [21] Survival of patients with advanced pancreatic cancer is increased by nab-paclitaxel plus gemcitabine
    Nature Reviews Gastroenterology & Hepatology, 2013, 10 (12) : 695 - 695
  • [22] Efficacy of prophylactic minocycline treatment for skin toxicities induced by erlotinib plus gemcitabine in advanced pancreatic cancer patients
    Shinohara, Akira
    Okuyama, Hiroyuki
    Kuwahara, Akiko
    Kobayashi, Misaki
    Takahashi, Hideaki
    Ohno, Izumi
    Shimizu, Satoshi
    Mitsunaga, Shuichi
    Saitoh, Shinichiro
    Ikeda, Masafumi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [23] RANDOMIZED CROSS-OVER AIO PHASE III TRIAL COMPARING GEMCITABINE PLUS ERLOTINIB FOLLOWED BY CAPECITABINE VS. CAPECITABINE PLUS ERLOTINIB FOLLOWED BY GEMCITABINE IN ADVANCED PANCREATIC CANCER
    Boeck, S.
    Vehling-Kaiser, U.
    Waldschmidt, D.
    Kettner, E.
    Maerten, A.
    Winkelmann, C.
    Klein, S.
    Kojouharoff, G.
    Jung, A.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2010, 21 : 233 - 233
  • [24] Phase I Trial of Gemcitabine Combined with Capecitabine and Erlotinib in Advanced Pancreatic Cancer: A Clinical and Pharmacological Study
    Francois, E.
    Bennouna, J.
    Chamorey, E.
    Etienne-Grimaldi, M. C.
    Renee, N.
    Senellart, H.
    Michel, C.
    Follana, P.
    Mari, V.
    Douillard, J. Y.
    Milano, G.
    CHEMOTHERAPY, 2012, 58 (05) : 371 - 380
  • [25] Improvements in survival and clinical benefit with the use of gemcitabine (GEM) as first-line therapy for advanced pancreatic cancer: A randomized trial
    Moore, M
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 547 - 547
  • [26] A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer
    Sanghvi, Samrat M.
    Coffman, Alex R.
    Hsueh, Chung-Tsen
    Kang, Joseph
    Park, Annie
    Solomon, Naveenraj L.
    Garberoglio, Carlos A.
    Reeves, Mark E.
    Slater, Jerry D.
    Yang, Gary Y.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, : 1989 - 1996
  • [27] GEMCITABINE (G) FIXED RATE DOSE INFUSION (FDR) PLUS ERLOTINIB (E) IN PATIENTS WITH ADVANCED PANCREATIC CANCER (APC)
    Munoz, A.
    Azkona, E.
    Iza, E.
    Martinez, M.
    Lopez-Vivanco, G.
    Fernandez, R.
    Ruiz De Lobera, A.
    Rubio, I.
    Casas, R.
    Mane, J. M.
    ANNALS OF ONCOLOGY, 2010, 21 : 235 - 235
  • [28] Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis
    Wang, Yuan
    Hu, Guo-fang
    Zhang, Qian-qian
    Tang, Ning
    Guo, Jun
    Liu, Li-yan
    Han, Xiao
    Wang, Xia
    Wang, Zhe-hai
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 1961 - 1972
  • [29] Analysis of axitinib (AG-013736) plus gemcitabine in patients with advanced pancreatic cancer: Diastolic blood pressure as biomarker of clinical benefit
    Spano, J.
    Maurel, J.
    Wasan, H.
    Bycott, P.
    Liau, K.
    Pithavala, Y.
    Garrett, M.
    Ricart, A.
    Kim, S.
    Chockiewicz, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 11 - 11
  • [30] Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG].
    Moore, MJ
    Goldstein, D
    Hamm, J
    Figer, A
    Hecht, J
    Gallinger, S
    Au, H
    Ding, K
    Christy-Bittel, J
    Parulekar, W
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1S - 1S
12345